Resonate Blends, INC

James Morrison resigns as President/CEO of Resonate Blends, while remaining on the Board of Directors, and James W. Zimbler is appointed as the new President/CEO, effective March 5, 2025.

Resonate Blends, Inc. has reformed its share exchange agreement with Emergent Health Corp. into a share-for-asset structure and appointed two new directors to its board.

Resonate Blends, Inc. finalized a share exchange agreement with Emergent Health Corp., divested its subsidiary, and appointed a new board of directors and executive team.

Resonate Blends, Inc. finalized a share exchange agreement with Emergent Health Corp., resulting in a major shift in ownership and management, while also divesting a subsidiary.

Resonate Blends, Inc. amended its Share Exchange Agreement with Emergent Health Corp., lowering the minimum investment required prior to closing from $500,000 to $250,000.

Resonate Blends, Inc. will acquire Emergent Health Corp. through a share exchange, resulting in a major restructuring and a change in company direction.

Resonate Blends, Inc. (KOAN) reported a reduced net loss for Q1 2025, driven by increased sales from its new biowellness assets, but continues to face substantial doubt about its ability to continue as a going concern due to a large accumulated deficit and reliance on dilutive financing.

Resonate Blends, Inc. reports a significant increase in revenue for the nine months ended September 30, 2024, primarily due to the acquisition of Emergent Health Corp. assets, but also discloses ongoing concerns about its ability to continue as a going concern.

Resonate Blends, Inc. reports a significant increase in revenue for the six months ended June 30, 2024, primarily due to the acquisition of assets from Emergent Health Corp., but also identifies material weaknesses in internal controls.

Resonate Blends' Q1 2024 results show increased revenue due to the Emergent Health Corp. acquisition, but also a significant net loss increase.

Resonate Blends, Inc. reported a substantial increase in net loss and working capital deficit for the fiscal year ended December 31, 2024, raising significant doubt about its ability to continue as a going concern, despite a surge in revenue driven by a recent acquisition.

Resonate Blends, Inc. (KOAN) reported a significant increase in net loss and working capital deficit for the fiscal year ended December 31, 2024, prompting auditors to raise substantial doubt about its ability to continue as a going concern.

Resonate Blends Inc. reports its 2023 financial results, highlighting a significant net loss and a major strategic shift following the acquisition of Emergent Health Corp.

Resonate Blends, Inc. announces a corporate name change to Apollo Biowellness, Inc. and an increase in authorized preferred stock from 10 million to 75 million shares, approved by a majority shareholder via written consent.

Resonate Blends is increasing its authorized common stock from 200 million to 2 billion shares to enhance its financing and capital-raising capabilities.